pegfilgrastim

Also known as N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene), Pluripoietin, G-CSF, Granulocyte colony-stimulating factor precursor

Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.

Chemical data

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Protein
First approval: 2002
Admin. routes: parenteral
Indications: leukemia, non-Hodgkins lymphoma, multiple myeloma, breast carcinoma

via ChEMBL · EBI

Research

1,251 papers

Pegfilgrastim.Drugs · 2002
Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019
Pegfilgrastim.Expert opinion on biological therapy · 2002
Two decades of pegfilgrastim: what have we learned? Where do we go from here?Current medical research and opinion · 2023
Pharmacokinetics of pegfilgrastim.Pharmacotherapy · 2003

via PubMed

Wikidata facts

Has use: medication

Show 5 more facts

medical condition treated: lymphoma
World Health Organisation international non-proprietary name: pegfilgrastim
defined daily dose: 0.3
NCI Thesaurus ID: C1854
has characteristic: biopharmaceutical

Sources (6)

via Wikidata · CC0

~3 min read

Encyclopedic overview

4 sections

Contents

Medical uses
Society and culture
Legal status
References

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.

Excerpted from Wikipedia’s “pegfilgrastim” article, available under the CC BY-SA 4.0 licence.

Available in 14 languages

via Wikidata sitelinks · CC0